The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 ...
Introducing a new RNA-seq platform for intracellular multimodal profiling that could transform cancer research and ...
Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results